Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. (BEAM) is a healthcare company (biotechnology) based in the United States. The share price is $20.91, down 0.14% on the day, which values the company at $2.16B. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$20.91−0.14% today
Market value
$2.16B
Funk Score
59/100
Against its own history
Well below its usual priceusual price $43.10
200-week average
$26.5721% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Beam Therapeutics Inc. in more detail

BEAM trades at -4.1× next year's expected earnings, 14.8× sales. Measured against its own history, the price is 51% below what its usual multiples would imply ($43.10) — well below its usual price. It sits 21% below its 200-week average of $26.57.

Over the last five fiscal years Beam Therapeutics Inc. has compounded revenue 466.3% a year. Its Funk Score is 59 out of 100 (financial strength 7.4, profitability 2.0, growth 9.3, value 5.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.

3 of the superinvestors tracked here hold BEAM, including Cathie Wood (1.7% of the portfolio), Andrew Spokes (1.3% of the portfolio), Stanley Druckenmiller (0.1% of the portfolio).

Superinvestors holding BEAM

3 of the investors tracked here report a position in their latest 13F filing.

Beam Therapeutics Inc. (BEAM): questions and answers

What is Beam Therapeutics Inc.'s market cap?

Beam Therapeutics Inc. is valued at $2.16B at a share price of $20.91.

Is BEAM overvalued or undervalued?

Against its own history, BEAM is well below its usual price: the price is 51% below the $43.10 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is BEAM above its 200-week moving average?

No. BEAM is 21.3% below its 200-week average of $26.57. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Beam Therapeutics Inc. growing?

Over the last five fiscal years Beam Therapeutics Inc.'s revenue grew 466.3% a year.

Does BEAM pay a dividend?

Beam Therapeutics Inc. does not currently pay a regular dividend.

Which famous investors own BEAM?

In their latest quarterly filings, Cathie Wood (1.7% of the portfolio), Andrew Spokes (1.3% of the portfolio), Stanley Druckenmiller (0.1% of the portfolio) hold BEAM. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Beam Therapeutics Inc. (BEAM) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BEAM

Underlying data: Yahoo Finance; company filings with the SEC.